We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
- Authors
Schouten, Jeffrey T; Krambrink, Amy; Ribaudo, Heather J; Kmack, Anne; Webb, Nancy; Shikuma, Cecilia; Kuritzkes, Daniel R; Gulick, Roy M
- Abstract
In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine. Most adverse events resolved; 15 participants ultimately discontinued nevirapine therapy. Grade 3/4 hepatotoxicity was observed in 14% of individuals who substituted nevirapine, compared with 6% who continued efavirenz therapy. Substitution of nevirapine because of efavirenz toxicity was generally safe and efficacious. Clinical trials registration. NCT00013520 .
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Vol 50, Issue 5, p787
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/650539